Several brokerages have updated their recommendations and price targets on shares of Innoviva (NASDAQ: INVA) in the last few weeks:
- 8/11/2026 – Innoviva was downgraded by Weiss Ratings from “buy (b)” to “hold (c+)”.
- 8/7/2026 – Innoviva had its price target lowered by Cantor Fitzgerald from $36.00 to $34.00. They now have an “overweight” rating on the stock.
- 8/1/2026 – Innoviva was downgraded by Wall Street Zen from “buy” to “hold”.
- 7/31/2026 – Innoviva was downgraded by Zacks Research from “hold” to “strong sell”.
- 6/24/2026 – Innoviva had its “buy (b)” rating reaffirmed by Weiss Ratings.
- 6/22/2026 – Innoviva had its “buy” rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.
The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.
Featured Stories
- Five stocks we like better than Innoviva
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Innoviva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc and related companies with MarketBeat.com's FREE daily email newsletter.
